Scalable liquid biopsies
for precision medicine
We develop versatile chemistry and statistical algorithms that plug into existing PCR hardware for a new generation of rapid, high-performance diagnostics.
Scalable liquid biopsies for precision medicine
We develop versatile chemistry and statistical algorithms that plug into existing PCR hardware for fast and comprehensive diagnostics.
Our initial focus: severe infections in hospitalized patients
Without swift intervention, some infections evolve into medical emergencies. Current diagnostics rely on "blood culture" which takes days and often fails altogether, forcing doctors to treat many patients while knowing little about the pathogens involved.
Rapid DNA-based blood tests ("liquid biopsies") are urgently needed, but for them to change how doctors manage critically ill patients, they must be
-
Comprehensive: covering dozens to hundreds of pathogens rather than just the "usual suspects."
-
Sensitive and Specific: detecting low levels of pathogens while accounting for trace microbial DNA in patients without infections.
-
Simple: with streamlined and cost-effective integration into busy hospital labs.
We are solving this problem with existing PCR hardware
"Digital PCR" uses microfluidics to quantify single molecules of DNA, which could help distinguish true infections from trace background. It's simple, cost-effective, and gaining traction in clinical labs.
​
We are developing compatible test kits to bring comprehensive coverage to digital PCR:
-
Our DNA "keyword" sensors distinguish 100's of pathogen genes based on their combinations of keywords.
- Our statistical algorithms analyze 100,000 datapoints from parallel reactions to determine the sample content.​
Our Envisioned Impact
Culture-free, comprehensive, and quantitative liquid biopsies to improve and personalize care
1. Target
Rapid pathogen diagnostics help clinicians select targeted therapies and can hint at the original source of infection.
2. Monitor
Quantitative tracking could allow doctors to follow their patients' progress, adjust course if necessary, and de-escalate at the right time.
3. Decentralize
High-performance yet practical, PCR-based testing could be brought to most community hospitals to serve critically ill patients at the point-of-care.
Product under development. Performance and clinical impact have not been validated.
Get in Touch
Whether you are interested in working with us or just want to say hello, please reach out.